Oncology Clinical Pathways Spotlight
This week in health care trends, our oncology clinical pathways spotlight includes the impact of clinical pathways on practices’ workloads and the shift toward precision medicine in clinical trials.
The articles below are from our dedicated Oncology Clinical Pathways e-magazine. We’re constantly adding valuable content to this updateable magazine, so make sure to check out this e-magazine (and others) frequently for new intelligence. You can follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)
In a recent study, Healthcare Research and Analytics found that “for almost seven out of ten oncologists, clinical pathways incur an administrative burden on their practices. This reduces the time the oncologist and their staff have for treating patients.”
Recently the National Cancer Institute announced it will be launching “a nationwide trial to test treatments based on the genetic mutations in patients’ tumors, rather than on where the tumors occur in the body.” This is just the latest step in a larger shift away from location-specific cancer study and towards genetically-based cancer study, as a part of President Obama’s “Precision Medicine” initiative.
ASCO Plans to Release Conceptual Value Framework to Assess the Value of New Cancer Treatment Options
ASCO has announced the release of their Value Framework to “serve as the basis for user-friendly, standardized tools that physicians can use with their patients to discuss the relative value of new cancer therapies as treatment options.”
In their recently released Value Framework, ASCO “rates treatment regimens on a 0-to-100 scale–0-to-130 in some cases, with bonus points–and the physicians’ group hasn’t been shy about awarding low scores,” including a zero for one combination therapy.